G1 Therapeutics Inc (GTHX)

$3.91

-0.04

(-1.01%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $3.86
    $4.05
    $3.91
    downward going graph

    1.28%

    Downside

    Day's Volatility :4.69%

    Upside

    3.46%

    downward going graph
  • $1.08
    $6.14
    $3.91
    downward going graph

    72.38%

    Downside

    52 Weeks Volatility :82.41%

    Upside

    36.32%

    downward going graph

Returns

PeriodG1 Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-1.0%
6.5%
0.0%
6 Months
-3.19%
7.1%
0.0%
1 Year
65.97%
9.8%
0.0%
3 Years
-77.6%
14.2%
-20.2%

Highlights

Market Capitalization
196.1M
Book Value
$0.53
Earnings Per Share (EPS)
-0.6
PEG Ratio
0.0
Wall Street Target Price
4.5
Profit Margin
-36.4%
Operating Margin TTM
-62.5%
Return On Assets TTM
-10.81%
Return On Equity TTM
-84.13%
Revenue TTM
84.0M
Revenue Per Share TTM
1.62
Quarterly Revenue Growth YOY
11.799999999999999%
Gross Profit TTM
47.6M
EBITDA
-22.3M
Diluted Eps TTM
-0.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.5
EPS Estimate Next Year
-0.22
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    83%Buy
    8%Hold
    8%Sell
Based on 12 Wall street analysts offering stock ratings for G1 Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 15.09%

Current $3.91
Target $4.50

Technicals Summary

Sell

Neutral

Buy

G1 Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
G1 Therapeutics Inc
G1 Therapeutics Inc
75.56%
-3.19%
65.97%
-77.6%
-85.07%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
G1 Therapeutics Inc
G1 Therapeutics Inc
NA
NA
0.0
-0.5
-0.84
-0.11
NA
0.53
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
G1 Therapeutics Inc
G1 Therapeutics Inc
Buy
$196.1M
-85.07%
NA
-36.4%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on G1 Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 14.87M → 14.47M (in $), with an average decrease of 2.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -18.20M → -10.21M (in $), with an average increase of 36.9% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 264.1%

Institutional Holdings

  • Vanguard Group Inc

    3.98%

  • Susquehanna International Group, LLP

    1.82%

  • Renaissance Technologies Corp

    1.73%

  • Raymond James & Associates

    1.54%

  • D. E. Shaw & Co LP

    1.50%

  • BlackRock Inc

    1.29%

Company Information

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.

Organization
G1 Therapeutics Inc
Employees
100
CEO
Mr. John E. Bailey Jr.
Industry
Health Technology

Discover More

FAQs